Developing vaccines targeting RAS and KRAS mutations represents a significant advance in the field of personalized cancer treatments, with the aim of improving the survival rates of PDA patients by harnessing the immune system to specifically recognize and target tumor cells that harbor these mutations. The gene discussed is KRAS; the disease is neoplasm.